Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Vivanza Biosciences Ltd Fundamentals

Market Cap
₹ 28.72 Cr
P/E Ratio (TTM)
51.29
P/B Ratio
6.19
Debt to Equity
1.78
ROE
13.57
EPS (TTM)
0.14
Dividend Yield
0.00 %
Book Value
1.16

Click here to know more about Fundamentals

Vivanza Biosciences Ltd Financials

Vivanza Biosciences Ltd Financials

Vivanza Biosciences Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 43.24 % 44.90 % 47.29 % 47.80 %
Others 42.94 % 46.04 % 46.48 % 46.54 %
Retail 13.82 % 9.06 % 6.23 % 5.66 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

43.24%

Others

42.94%

Retail

13.82%

Mutual Funds

0.00%

FII

0.00%

Promoters

44.90%

Others

46.04%

Retail

9.06%

Mutual Funds

0.00%

FII

0.00%

Promoters

47.29%

Others

46.48%

Retail

6.23%

Mutual Funds

0.00%

FII

0.00%

Promoters

47.80%

Others

46.54%

Retail

5.66%

Mutual Funds

0.00%

FII

0.00%

Resistance and Support

₹7.20

PIVOT

resistance-arrow
Resistance
First Resistance₹7.407
Second Resistance₹7.633
Third Resistance₹7.837
support-arrow
Support
First Support₹6.977
Second Support₹6.773
Third Support₹6.547

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day26,14126,141100.00
Week26,141122,1150.00
1 Month26,141676,3170.00
6 Months30,152,89025,977,18595.11

About Vivanza Biosciences Ltd

Vivanza Biosciences Ltd (Previously known Ivee Injectaa Limited) was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Head quartered in Gujarat, India, the Company came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. The Company is presently engaged in the business of Pharmaceutical Products and Pharma Products. However Competition in the industry is continuously increasing. New technology is being adopted and steps are taken to improve the manufacturing capacity of the Company. Further, the Company has also set its vision in global market to supply and execute turnkey pharmaceutical units. The company undertook an expansion-cum-diversification programme to increase its capacity from 18 lac pa to 54 lac pa. It also proposed to diversify into the manufacture of small volume parenterals with an installed capacity of 294 lac pa. It came out with a public issue of 21,70,000 equity shares of Rs 10 each for cash at par aggregating Rs 217 lac. It is one of the few companies which has facilities for both glass as well as plastic containers. Due to recessionary trends which lead to difficult business conditions in the year 1999-2000, the parenteral industry suffered a setback. As a result of this, the name of the Company was changed from Ivee Injectaa Ltd. to Vivanza Biosciences Ltd in 2015. The Company acquired 100% Equity Shares of Vivanza Lifesciences Private Limited and by virtue of the holding in Vivanza Lifesciences Private Limited it became Wholly Owned Subsidiary w.e.f. 17/06/2016.

Managing Director

1982

Founded

Jayendra Mehta

NSE Symbol

NA

Vivanza Biosciences Ltd Management

NameDesignation
Hemant ParikhDirector
Sunil ShahIndependent Director
Avinash G. BhojwaniCompany Sec. & Compli. Officer
Apeksha VyasIndependent Director
Jayendra MehtaManaging Director

Vivanza Biosciences Ltd News

Vivanza Biosciences reports consolidated net loss of Rs 0.41 crore in the March 2024 quarter
Sales decline 46.36% to Rs 4.42 crore
Vivanza Biosciences to hold board meeting
On 30 April 2024
Vivanza Biosciences consolidated net profit declines 54.35% in the December 2023 quarter
Sales rise 11.95% to Rs 6.56 crore
Vivanza Biosciences to convene board meeting
On 6 February 2024
Vivanza Biosciences consolidated net profit rises 52.94% in the September 2023 quarter
Sales rise 464.44% to Rs 7.62 crore
Vivanza Biosciences standalone net profit rises 26.67% in the September 2023 quarter
Sales rise 272.12% to Rs 3.87 crore
Vivanza Biosciences to announce Quarterly Result
On 26 October 2023
Vivanza Biosciences consolidated net profit rises 600.00% in the June 2023 quarter
Sales rise 292.77% to Rs 9.23 crore
Vivanza Biosciences to hold board meeting
On 10 August 2023
Vivanza Biosciences AGM scheduled
On 24 July 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Adani Enterprises Ltd₹ 348811.84 Cr
₹ 3,059.75
(-0.02 %)
122.71
Aegis Logistics Ltd₹ 22144.59 Cr
₹ 630.90
(4.91 %)
50.17
Cello World Ltd₹ 19996.41 Cr
₹ 942.20
(-0.07 %)
0.00
Redington Ltd₹ 16491.53 Cr
₹ 210.95
(-0.12 %)
15.26
Honasa Consumer Ltd₹ 13182.15 Cr
₹ 406.55
(1.59 %)
138.21

Vivanza Biosciences Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Vivanza Biosciences Ltd shares in BlinkX

Vivanza Biosciences Ltd's P/E ratio is 51.29 times as of May 18, 2024 at 04:00 PM.

Vivanza Biosciences Ltd's most recent financial reports indicate a price-to-book ratio of 6.19, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Vivanza Biosciences Ltd's market is 29 Cr as on May 18, 2024 at 04:00 PM.

The current financial records of Vivanza Biosciences Ltd show a 13.57% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Vivanza Biosciences Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Vivanza Biosciences Ltd stands at 43.24%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.